Medscape (4/22, Kirkner, Subscription Publication) reports, “SEP-363856, an investigational nondopamine antipsychotic that’s been the focus of a trial in schizophrenia, has shown signals that it may improve psychosis symptoms in patients with Parkinson’s disease without worsening motor symptoms,” researchers concluded in a 38-patient, “proof-of-principle study presented at the 2021” virtual annual meeting of the American Academy of Neurology. (SOURCE: APA Headlines)